查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016232

可吸收血管支架市場：依適應症、材料、支架直徑、支架長度及最終用戶分類－2026-2032年全球市場預測

Resorbable Vascular Scaffold Market by Indication, Material, Scaffold Diameter, Scaffold Length, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，可吸收血管支架市場價值將達到 4.6465 億美元，到 2026 年將成長至 5.0068 億美元，到 2032 年將達到 7.7998 億美元，複合年成長率為 7.68%。

主要市場統計數據
基準年 2025 4.6465億美元
預計年份：2026年 5.068億美元
預測年份：2032年 7.7998億美元
複合年成長率 (%) 7.68%

對可吸收血管支架的臨床機會、工程原理、監管環境和相關人員趨勢進行權威說明。

可吸收血管支架是材料科學與介入性心臟病學融合的產物，旨在恢復血管通暢性，同時避免長期植入永久性金屬植入。其設計理念是在血管治療期間提供臨時機械支撐和可控藥物釋放型，隨後逐漸被吸收，可能會減少與永久性植入相關的延遲性不利事件。本導論分析系統地說明了推動臨床應用進展的技術進步、臨床促進因素以及相關人員生態系統。

重建可吸收血管支架的前景：定義材料科學、手術實務和臨床證據的顛覆性轉折點。

可吸收血管支架的前景已從概念性的可能性轉變為實際的工程和臨床改進。鎂合金和聚乳酸衍生物等生物可吸收材料的進步提高了徑向強度、可控的分解速率和生物相容性。同時，裝置結構的迭代改進（例如減薄支架梁、最佳化支架形態、開發新一代藥物塗層等）緩解了最初對支架血栓症和血管回縮的擔憂。血管內成像技術和操作流程的改進降低了植入的變異性，而藥物釋放型支架的跨學科經驗正被應用於最佳化抗血小板策略和最佳植入實踐。

評估 2025 年美國對可吸收血管支架國際供應鏈徵收關稅對營運、採購和創新的綜合影響。

對醫療設備零件和成品徵收關稅可能會對可吸收血管支架的研發和商業化產生多方面的影響。關稅帶來的成本壓力將使依賴國際供應鏈獲取關鍵投入（例如特種合金、聚合物原料和精密製造設備）的製造商的採購變得更加複雜。因此，核准的價格上漲和利潤率下降可能會減緩對臨床試驗、生產規模擴大和全球市場准入計畫的投資。隨著醫療設備定價趨勢的變化，醫院採購部門可能會重新評估其採購決策，而報銷談判也可能越來越關注治療總成本和生命週期經濟效益，而不僅僅是單價。

深入分析了與臨床適應症、支架材料、設備尺寸和最終用戶環境相關的細分，這些因素影響著治療管道和應用。

從細分觀點來看，適應症、材料、最終用戶狀況、支架直徑和支架長度如何影響臨床選擇、裝置設計優先順序和商業性定位就顯而易見了。就適應症而言，臨床環境分為冠狀動脈疾病和周邊動脈疾病，其中冠狀動脈疾病又細分為急性冠狀動脈症候群和穩定性心絞痛。周邊動脈疾病則進一步分為間歇性跛行和嚴重下肢缺血。每種臨床途徑都需要不同的機械性質和藥物釋放型策略。在急性冠狀動脈介入治療中，快速釋放和可控吸收通常是優先考慮的因素，以利於早期治療；而周邊肢體缺血介入治療則需要長期徑向強度和更高的抗壓強度。

區域展望整合了美洲、歐洲、中東、非洲和亞太地區的臨床基礎設施、法規結構、報銷趨勢和部署模式。

美洲、歐洲、中東、非洲和亞太地區的臨床基礎設施、法規結構、報銷管道和醫療專業人員偏好等因素，導致區域績效和應用趨勢有顯著差異。在美洲，集中的介入治療專業中心和高頻次的冠狀動脈介入治療課程有助於快速掌握技能並儘早應用。該地區的監管流程和與支付方的談判強調可靠的臨床終點和長期安全性，促使製造商除了提供隨機對照試驗數據外，還需提供成熟的上市後數據。

針對支架製造商之間的合作關係、臨床研發管線、生產規模、智慧財產權定位和競爭優勢等方面的策略競爭情報。

可吸收血管支架研發企業的競爭格局受臨床證據的累積、生產規模、智慧財產權差異化和商業性夥伴關係等因素的影響。主要企業憑藉強大的臨床研發管線脫穎而出，這些管線能夠證明產品在多種冠狀動脈和周邊血管適應症中的安全性；而其他企業則專注於提升生產能力，以確保產品性能穩定並符合監管要求。與影像設備製造商、契約製造製造商和臨床研究機構建立合作關係可以加速證據的累積並促進市場准入。同時，企業內部的精密擠出和滅菌能力有助於品質和成本控制。

為製造商、臨床醫生和投資者提供實用建議，以加速臨床應用並降低商業性和程序風險。

產業領導企業可以採取切實措施，在應對臨床和商業性不確定性的同時，加速產品應用。首先，將臨床開發項目與不同的適應症管道相匹配。優先考慮那些瞬時支架能夠帶來明確治療益處的高影響力適應症，並設計包含影像學和患者報告結果的測試，以增強產品的價值主張。其次，透過原料來源多元化和評估區域製造地，投資於價值鏈的韌性，以減輕貿易政策波動的影響，並確保向高使用率設施提供可預測的設備供應。

採用混合方法研究途徑，結合專家訪談、臨床文獻綜述、註冊分析和供應鏈檢驗。

本分析的調查方法融合了定性和定量方法，以確保獲得可靠且可操作的見解。主要調查包括對介入性心臟病專家、周邊血管專家、採購經理和監管專家進行結構化訪談，以了解他們對器械性能、手術流程和採購重點的實際觀點。次要調查包括對同行評審的臨床文獻、器械註冊資訊、監管申報文件和專利資訊披露進行系統性回顧，以全面檢驗臨床結果、安全訊號和技術趨勢。

總結了影響可吸收支架未來發展和商業性成功的策略挑戰、持續存在的障礙以及關鍵成功因素。

總之，可吸收血管支架在臨床應用潛力和工程創新方面展現出令人矚目的優勢，但其成功應用於常規臨床實踐取決於材料科學、實證醫學證據、監管策略和商業性實施等方面的協調進展。目前仍存在許多障礙，包括需要長期安全性數據、供應鏈韌性以應對貿易政策波動，以及與支付方建立清晰的溝通管道，這些支付方不僅考慮單位成本，還關注整個生命週期的效益。然而，如果這些障礙得以克服，支架技術有望在特定冠狀動脈和周邊血管疾病的治療中帶來變革性轉變。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 可吸收血管支架市場：依適應症分類

  • 冠狀動脈疾病
    • 急性冠狀動脈症候群
    • 穩定性心絞痛
  • 周邊動脈疾病
    • 間歇性跛行
    • 嚴重下肢缺血

第9章：可吸收血管支架市場：依材料分類

  • 鎂
  • 聚乳酸

第10章 可吸收血管支架市場：依支架直徑分類

  • 3毫米或更小
  • 3毫米或以上

第11章 可吸收血管支架市場：依支架長度分類

  • 18～28mm
  • 超過 28 毫米
  • 18毫米或更小

第12章 可吸收血管支架市場：依最終用戶分類

  • 門診手術中心
  • 心臟中心
  • 醫院

第13章 可吸收血管支架市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 可吸收血管支架市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 可吸收血管支架市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國可吸收血管支架市場

第17章：中國可吸收血管支架市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • BIoTronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardionovum GmbH
  • Elixir Medical Corporation
  • Meril Life Sciences Private Limited
  • MicroPort Scientific Corporation
  • Shandong Huaan BIoTechnology Co., Ltd.
  • Terumo Corporation
  • Xeltis AG
  • Zorion Medical
Product Code: MRR-035AB9C0DAAB

The Resorbable Vascular Scaffold Market was valued at USD 464.65 million in 2025 and is projected to grow to USD 500.68 million in 2026, with a CAGR of 7.68%, reaching USD 779.98 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 464.65 million
Estimated Year [2026] USD 500.68 million
Forecast Year [2032] USD 779.98 million
CAGR (%) 7.68%

An authoritative introduction to clinical opportunity, engineering principles, regulatory landscape, stakeholder dynamics around resorbable vascular scaffolds

Resorbable vascular scaffolds represent a convergence of materials science and interventional cardiology intended to restore vessel patency while eliminating the long-term presence of a permanent metallic implant. The design rationale is to provide transient mechanical support and controlled drug elution during the period of vessel healing before gradual resorption, thereby potentially reducing late adverse events linked to permanent implants. This introductory analysis contextualizes technological evolution, clinical drivers, and the stakeholder ecosystem that together determine the pace of clinical integration.

Clinicians, device engineers, regulatory authorities, and hospital procurement teams each play a distinct role in value creation and risk mitigation. Clinicians demand robust safety and efficacy evidence across acute and chronic coronary presentations as well as peripheral arterial conditions. Engineers pursue thinner strut geometry, predictable degradation profiles, and optimized drug-polymer matrices to improve deliverability and reduce restenosis. Regulators emphasize long-term follow-up and imaging endpoints, while purchasers weigh procedural cost, inventory complexity, and reimbursement alignment. Taken together, these forces set the agenda for product development, clinical trial design, and go-to-market strategies that will define which scaffold concepts progress to routine clinical use.

Defining disruptive inflection points in materials science, procedural practice, and clinical evidence reshaping the resorbable vascular scaffold landscape

The landscape for resorbable vascular scaffolds has shifted from conceptual promise to pragmatic engineering and clinical refinement. Advances in bioresorbable materials such as magnesium alloys and polylactic acid derivatives have improved radial strength, controlled degradation kinetics, and biocompatibility. Simultaneously, iterative improvements in device architecture-thinner struts, enhanced scaffold geometries, and next-generation drug coatings-have mitigated early concerns around scaffold thrombosis and vessel recoil. Improved intravascular imaging and procedural techniques have reduced deployment variability, and cross-disciplinary learning from drug-eluting stents has informed optimal antiplatelet strategies and implantation best practices.

Beyond materials and technique, the evidence base has matured; post-market registries and focused randomized studies continue to refine the clinical niches where resorbable scaffolds provide incremental benefit. Regulatory approaches have evolved to balance accelerated access with demands for robust longitudinal safety data, prompting manufacturers to embed extended follow-up and imaging endpoints into development pathways. Economically, hospitals and payers increasingly demand clear value narratives tied to reduced long-term complications and simplified lifelong imaging or intervention. Together, these transformative shifts are realigning R&D priorities, shaping reimbursement conversations, and compressing the time from prototype to clinical adoption for technologies that can demonstrably improve patient outcomes.

Assessing compounded operational, procurement, and innovation consequences of 2025 US tariffs on international supply chains for resorbable vascular scaffolds

The introduction of tariffs affecting medical-device components and finished goods can exert a multi-dimensional impact on resorbable vascular scaffold development and commercialization. Tariff-driven cost pressures raise procurement complexity for manufacturers that rely on international supply chains for key inputs such as specialized alloys, polymer feedstocks, and precision manufacturing equipment. In turn, consented price increases or margin compression can slow investment in clinical trials, manufacturing scale-up, and global market entry plans. Hospital procurement teams may recalibrate purchasing decisions as device pricing dynamics shift, while reimbursement negotiations will increasingly factor in total cost of care and lifecycle economics rather than unit price alone.

Strategic responses to tariff-induced disruption include near-shoring of component manufacturing, renegotiation of supplier contracts, and redesign for material sourcing flexibility. These measures require lead time and capital allocation but can increase resilience against future policy volatility. In addition, device developers may accelerate development of cost-effective production processes or prioritize markets with favorable trade terms to preserve commercial momentum. Clinical adoption pathways may experience temporal variation as providers weigh the clinical advantages of resorbable solutions against short-term budgetary constraints, creating differentiated windows of opportunity across geographies and care settings.

Segmentation-focused insights into clinical indications, scaffold materials, device dimensions, and end-user settings that shape therapeutic pathways and adoption

A segmentation lens reveals how indication, material, end-user context, scaffold diameter, and scaffold length each inform clinical selection, device design priorities, and commercial positioning. Based on indication the clinical environment spans Coronary Artery Disease and Peripheral Arterial Disease, with Coronary presentations further divided into Acute Coronary Syndrome and Stable Angina, and Peripheral presentations distinguished between Claudication and Critical Limb Ischemia. These clinical pathways demand distinct mechanical profiles and drug-elution strategies: acute coronary interventions often prioritize rapid deliverability and controlled resorption to support early healing, while peripheral limb ischemia interventions require longer-term radial strength and enhanced durability against compressive forces.

Material segmentation across Magnesium and Polylactic Acid offers different trade-offs between strength, degradation timeline, and biocompatibility, which manifest in device handling and imaging profiles. End-user segmentation encompassing Ambulatory Surgical Centers, Cardiac Centers, and Hospitals drives differences in procedural volume, infrastructure, and purchasing cycles, thereby influencing inventory strategy and sales engagement models. Scaffold diameter segmentation distinguishing Less Than 3 Millimeter and Three Millimeter And Above categories directly affects device geometry and clinical indications, while scaffold length segmentation across Eighteen To Twenty Eight Millimeter, Greater Than Twenty Eight Millimeter, and Less Than Eighteen Millimeter brackets impacts delivery systems, overlapping strategies, and inventory breadth. Consequently, manufacturers must align material choice and dimensional platforms to specific clinical indications and end-user workflows to optimize adoption and economic viability.

Regional perspectives integrating clinical infrastructure, regulatory frameworks, reimbursement dynamics, and adoption patterns across Americas, EMEA and Asia-Pacific

Regional performance and adoption dynamics differ markedly and are shaped by clinical infrastructure, regulatory frameworks, reimbursement pathways, and practitioner preferences across Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas exhibit concentrated centers of interventional expertise and high-volume coronary programs that facilitate rapid procedural learning and early adopter behavior. Regulatory pathways and payer negotiations in this region emphasize robust clinical endpoints and long-term safety, which incentivizes manufacturers to present mature post-market evidence alongside randomized data.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and reimbursement models create a mosaic of access; several jurisdictions prioritize health-technology assessment criteria and long-term cost-effectiveness, prompting tailored market access strategies. Asia-Pacific includes markets with variable clinical capacity but high procedural growth, where scalable manufacturing and local regulatory engagement can accelerate penetration when coupled with clinician training programs. Across all regions, infrastructure for intravascular imaging, operator training ecosystems, and local reimbursement nuances determine the pace at which resorbable scaffolds shift from specialized centers to broader clinical practice. Consequently, a differentiated geographic strategy that aligns evidence generation and commercialization investments with regional clinical and payer priorities is essential for sustained uptake.

Strategic corporate intelligence on partnerships, clinical pipelines, manufacturing scale, IP positioning, and competitive differentiation among scaffold makers

Competitive dynamics among companies developing resorbable vascular scaffolds are shaped by clinical evidence generation, manufacturing scale, intellectual property differentiation, and commercial partnerships. Leading developers differentiate through robust clinical pipelines that demonstrate safety across diverse coronary and peripheral indications, while others emphasize manufacturing competence to ensure consistent device performance and regulatory compliance. Partnerships with imaging companies, contract manufacturers, and clinical research organizations can accelerate evidence generation and streamline market entry, whereas in-house capabilities in precision extrusion and sterilization provide control over quality and cost.

Corporate strategies increasingly include co-development agreements with hospital systems and specialist investigator networks to secure real-world data commitments and adoption pathways. Licensing arrangements and selective mergers or acquisitions can expand material science capabilities or geographic reach, but they also require careful integration planning to preserve clinical momentum. Intellectual property positioning around polymer formulations, alloy processing, and scaffold architecture remains a strategic asset and a lever in negotiations with potential partners. For companies and investors, success will hinge on the ability to synchronize clinical proof points with scalable manufacturing and targeted commercial rollouts that reflect differences in end-user requirements and regional access conditions.

Actionable recommendations for manufacturers, clinicians, and investors to accelerate clinical adoption and reduce commercial and procedural risk

Industry leaders can take concrete actions to accelerate adoption while managing clinical and commercial uncertainty. First, align clinical development programs with differentiated indication pathways; prioritize high-impact presentations where transient scaffolding offers clear therapeutic advantages and design trials that incorporate imaging and patient-reported outcomes to strengthen value narratives. Second, invest in supply chain resilience by diversifying raw material sources and evaluating localized manufacturing hubs to reduce exposure to trade policy shocks and to ensure predictable device supply to high-volume centers.

Third, engage proactively with payers and health-technology assessment bodies to establish reimbursement paradigms that reflect total cost of care and long-term benefits. Fourth, build clinician education programs that combine hands-on training with imaging-guided implantation protocols to reduce procedural variability and improve outcomes. Fifth, pursue strategic partnerships that combine materials expertise, manufacturing scale, and clinical trial infrastructure to shorten time-to-market while maintaining quality. Finally, adopt a phased commercialization strategy that sequences initial market entry into centers of excellence before broader roll-out, thereby accumulating real-world evidence and refining pricing and service models in response to early performance data.

Mixed-methods research approach integrating primary expert interviews, clinical literature review, registry analysis, and supply chain validation

The research methodology underpinning this analysis integrates qualitative and quantitative approaches to ensure robust and actionable findings. Primary research comprised structured interviews with interventional cardiologists, peripheral vascular specialists, procurement leaders, and regulatory experts to capture frontline perspectives on device performance, procedural workflows, and purchasing priorities. Secondary research included systematic review of peer-reviewed clinical literature, device registries, regulatory filings, and patent disclosures to triangulate clinical outcomes, safety signals, and technological innovation trends.

Supply chain mapping identified critical input dependencies and manufacturing bottlenecks, while commercial channel analysis examined hospital procurement processes and end-user adoption levers. Findings were validated through expert advisory panels and cross-checked with longitudinal device performance reports where available. Throughout the process, emphasis was placed on transparent documentation of data sources, methodological limitations, and assumptions to ensure that conclusions are reproducible and suitable for operational planning. This mixed-methods approach yields insights that are both clinically relevant and commercially executable.

Concluding synthesis of strategic imperatives, persistent barriers, and critical success factors shaping trajectory and commercial success of resorbable scaffolds

In conclusion, resorbable vascular scaffolds occupy a compelling nexus of clinical promise and engineering innovation, but their successful translation into routine practice depends on coordinated progress across materials science, evidence generation, regulatory strategy, and commercial execution. Persistent barriers include the need for long-term safety data, supply chain resilience in the face of trade policy fluctuations, and clear payer pathways that account for lifecycle benefits rather than unit price alone. Yet, where these barriers are addressed, scaffold technologies have the potential to change therapeutic paradigms for selected coronary and peripheral indications.

The pathway to success requires a disciplined alignment of device design with clinical indication, targeted evidence generation that responds to stakeholder concerns, and operational investments that secure reliable manufacturing and distribution. Organizations that integrate clinical leadership with agile supply chain strategies and clear reimbursement value propositions will be best positioned to realize the clinical and commercial benefits of resorbable scaffolds. Ultimately, the devices that combine practicable procedural workflows, demonstrable patient benefits, and sustainable economics will determine the technology's long-term role in vascular intervention.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Resorbable Vascular Scaffold Market, by Indication

  • 8.1. Coronary Artery Disease
    • 8.1.1. Acute Coronary Syndrome
    • 8.1.2. Stable Angina
  • 8.2. Peripheral Arterial Disease
    • 8.2.1. Claudication
    • 8.2.2. Critical Limb Ischemia

9. Resorbable Vascular Scaffold Market, by Material

  • 9.1. Magnesium
  • 9.2. Polylactic Acid

10. Resorbable Vascular Scaffold Market, by Scaffold Diameter

  • 10.1. Less Than 3 Millimeter
  • 10.2. Three Millimeter And Above

11. Resorbable Vascular Scaffold Market, by Scaffold Length

  • 11.1. Eighteen To Twenty Eight Millimeter
  • 11.2. Greater Than Twenty Eight Millimeter
  • 11.3. Less Than Eighteen Millimeter

12. Resorbable Vascular Scaffold Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Cardiac Centers
  • 12.3. Hospitals

13. Resorbable Vascular Scaffold Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Resorbable Vascular Scaffold Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Resorbable Vascular Scaffold Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Resorbable Vascular Scaffold Market

17. China Resorbable Vascular Scaffold Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Biotronik SE & Co. KG
  • 18.7. Boston Scientific Corporation
  • 18.8. Cardionovum GmbH
  • 18.9. Elixir Medical Corporation
  • 18.10. Meril Life Sciences Private Limited
  • 18.11. MicroPort Scientific Corporation
  • 18.12. Shandong Huaan Biotechnology Co., Ltd.
  • 18.13. Terumo Corporation
  • 18.14. Xeltis AG
  • 18.15. Zorion Medical

LIST OF FIGURES

  • FIGURE 1. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 134. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 136. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 138. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 158. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 159. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 160. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 161. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 162. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 166. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 167. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 168. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 170. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)